Short description:
Oncolytic Virus
Drug notes:
Also combo Clin2 bladder cancer, combo Clin1 bladder cancer
Long description:
CG Oncology is developing oncolytic immunotherapies to treat patients with advanced bladder cancer. Bladder cancer is the 4th most common form of cancer in men in the US. To address this CG is genetically engineering oncolytic immunotherapies. The therapy has a dual mechanism of action: first, the therapy infects and replicates inside tumor cells causing cell lysis. Secondly, the rupturing of cancer cells releases tumor-derived antigens that stimulates a systemic anti-tumor immune response. CG has 3 active clinical programs with their lead candidate, CG0070, showing remarkable efficacy in bladder cancer patients in their clinical trials.
Jobs:
QA SPECIALIST (GXP) Irvine, California, Stati Uniti d'America|3 days ago
Senior Manager, Data Management Irvine, California, Stati Uniti d'America|3 days ago
Senior Manager, Data Management Stati Uniti d'America|8 days ago
Product Manager (Urology Marketing) Stati Uniti d'America|8 days ago
Sr. Manager, Commercial Insights & Analytics United States|15 days ago
Sr. Manager, Commercial Insights & Analytics Irvine, California, Stati Uniti d'America|20 days ago
Senior Project Manager Irvine, California, Stati Uniti d'America|21 days ago
Medical Science Liaison United States|22 days ago
Senior Manager, Medical Writing Irvine, California, Stati Uniti d'America|31 days ago